Advertisement

Development of a New Formulation for Onychomycosis Treatment Using Furvina® as an Active Pharmaceutical Ingredient

  • Zenia Perez-RodriguezEmail author
  • Yaset Rodríguez-Rodríguez
  • Zenaida Rodriguez-Negrin
  • Reinaldo Molina-Ruiz
  • Ricardo Medina-Marrero
  • Evys Ancede-Gallardo
Conference paper

Abstract

The currently available treatments for onychomycosis are limited due to the absence of a formulation allowing the effective penetration of the active pharmaceutical ingredient (API). In this research, a chemical–pharmaceutical study over a new formulation for the treatment of onychomycosis, based on 2-bromo-5-(2-bromo-2-nitrovinyl) furan (Furvina) composed by 0.25% of this API, 1% urea as keratinizing agent and 98.75% benzyl alcohol as pharmaceutical vehicle, was performed. This tincture proved to be active against Candida albicans. In addition, an UV/Vis spectrophotometric analytic technique with a maximum absorption at 372 nm was developed and validated. This method was specific, precise, accurate, and linear in the range of 2–28 mg/L. The detection and quantification limits for this technique were 0.6567 and 0.6636 mg/L, respectively.

Keywords

Onychomycosis Furvina Spectrophotometric method UV/Vis Validation 

Notes

Acknowledgements

This study was supported by the Centro de Bioactivos Químicos (CBQ) through the Institutional Project 9656. The authors are indebted to MSc. Amalia María Calvo, MSc. Milagro García Bernal and Marlen Casanova González for their technical assistance and valuable help.

Conflict of Interest

Authors declare no conflict of interest regarding this publication.

References

  1. 1.
    Negrin ZR, de Rojas Perez M, Lovillo MP, Torres AM. Caracterización y cuantificación del compuesto resultante de la degradación por la luz del 2-(2-nitrovinil)-furano en estado sólido [Characterization and quantification of the resulting compound of the degradation by the light of the 2 (2-nitrovinil)-fura]Google Scholar
  2. 2.
    DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: new estimates of drug development costs. J. Health Econ 22:151–185.  https://doi.org/10.1016/s0167-6296(02)00126-1CrossRefGoogle Scholar
  3. 3.
    Welsh O, Vera-Cabrera L, Welsh E (2010) OnychomycosisGoogle Scholar
  4. 4.
    Ballesté R, Mousqués N, Gezuele E (2003) Onicomicosis: Revisión del tema. Rev Méd Urug 19:93–106Google Scholar
  5. 5.
    Scher RK, Nakamura N, Tavakkol A (2014) Luliconazole: a review of a new antifungal agent for the topical treatment of onychomycosis. Mycoses 57:389–393.  https://doi.org/10.1111/myc.12168CrossRefGoogle Scholar
  6. 6.
    Conti-Díaz IA (1964) Mycological study of 85 cases of onychopathy. An Fac Med Univ Montevideo. cabdirect.orgGoogle Scholar
  7. 7.
    Carrillo-Muñoz AJ, Tur-Tur C, Hernández-Molina JM, Santos P, Cárdenes D, Giusiano G (2010) Antifúngicos disponibles para el tratamiento de las micosis ungueales. Rev Iberoam Micol 27:49–56CrossRefGoogle Scholar
  8. 8.
    de Bedout C, Tabares A, Cano L, Restrepo A (2015) Comportamiento de los agentes etiológicos de las onicomicosis en un laboratorio de micologia de referencia (Medellín 1994–2003)Google Scholar
  9. 9.
    Arenas R (1990) Las onicomicosis. Aspectos clínico-epidemiológicos, micológicos y terapéuticos. Gac Med Méx. bases.bireme.brGoogle Scholar
  10. 10.
    Fabbretti A, Brandi L, Petrelli D, Pon CL, Castanedo NR, Medina R, Gualerzi CO (2012) The antibiotic Furvina® targets the P-site of 30S ribosomal subunits and inhibits translation initiation displaying start codon bias. Nucleic Acids Res. academic.oup.comGoogle Scholar
  11. 11.
    Sifontes-Rodríguez S, Monzote-Fidalgo L, Castañedo-Cancio N, Montalvo-Álvarez AM, López-Hernández Y, Diogo NM, Infante-Bourzac JF, Pérez-Martín O, Meneses-Marcel A, García-Trevijano JA, Cabrera-Pérez MÁ. The efficacy of 2-nitrovinylfuran derivatives againstLeishmania in vitro and in vivo. SciELO BrasilGoogle Scholar
  12. 12.
    Morales-Moreno Y, Medina-Marrero R, Garcia-Bernal M, Casanova-González M, Rodríguez-Pérez R, Fernández-López N, Guerra-Martínez M, Gómez-Marrero R, Rojas-Hernández N (2014) Actividad in vitro de furvina frente a bacterias Gram negativas multirresistentes. Rev CENIC Cienc Biol. redalyc.orgGoogle Scholar
  13. 13.
    Rowe RC, Sheskey PJ, Weller PJ (2006) Handbook of pharmaceutical excipientsGoogle Scholar
  14. 14.
    Beckett AH, Stenlake JB (1988) Practical pharmaceutical chemistry. Athlone PressGoogle Scholar
  15. 15.
    Branch SK (2005) Guidelines from the international conference on harmonisation (ICH). J Pharm Biomed Anal. ElsevierGoogle Scholar
  16. 16.
    Centro para el Control Estatal de la Calidad de los Medicamentos (CECMED) (2007) Regulación No. 41-2007: Validación de métodos analíticos. Ámbito ReguladorGoogle Scholar
  17. 17.
    Gomes GC, Salgado HRN (2005) Validation of UV spectrophotometric method for determination of lomefloxacin in pharmaceutical dosage form. Acta Farm Bonaer 24:406Google Scholar
  18. 18.
    Castro Cels M, Gascón Fora S, Pujol Forn M, Sanc Roca JM, Vicente Plas L (1989) Validación de métodos analíticos. Asociación Española de Farmaceúticos de la IndustriaGoogle Scholar
  19. 19.
    D’Este P (2002) The distinctive patterns of capabilities accumulation and inter‐firm heterogeneity: the case of the Spanish pharmaceutical industry. Ind Corp Change. academic.oup.comGoogle Scholar
  20. 20.
    Pérez M (2008) Desarrollo y validación de técnicas analíticas por HPLC y SQV, para determinar el contenido de UC-244Google Scholar
  21. 21.
    Castelli MV, Cozzi MV, López SN, Derita MG. Búsqueda de agentes conservantes a partir de productos naturales bioactivos, pp 63–67Google Scholar
  22. 22.
    De Beer J, Naert C, Deconinck E (2012) The quality coefficient as performance assessment parameter of straight line calibration curves in relationship with the number of calibration points. Accredit Qual Assur 17:265–274.  https://doi.org/10.1007/s00769-011-0871-1CrossRefGoogle Scholar
  23. 23.
    González A, Herrador M (2007) A practical guide to analytical method validation, including measurement uncertainty and accuracy profiles. TrAC Trends Anal Chem. ElsevierGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Zenia Perez-Rodriguez
    • 1
    Email author
  • Yaset Rodríguez-Rodríguez
    • 1
  • Zenaida Rodriguez-Negrin
    • 1
  • Reinaldo Molina-Ruiz
    • 1
  • Ricardo Medina-Marrero
    • 1
  • Evys Ancede-Gallardo
    • 1
  1. 1.Centro de Bioactivos Químicos (CBQ), Universidad Central “Marta Abreu” de Las VillasSanta ClaraCuba

Personalised recommendations